<DOC>
	<DOCNO>NCT01627587</DOCNO>
	<brief_summary>This two part study . Part A study evaluate metabolite GSK221149 follow single repeat oral dosing also assess pharmacokinetics GSK221149 administer potent CYP3A4 inhibitor Ketoconazole . Part B study look pharmacokinetics GSK221149 follow high fat meal .</brief_summary>
	<brief_title>A Two Cohort Study Look Metabolites GSK221149 , Metabolism GSK221149 Administered With High Fat Meal With Ketoconazole</brief_title>
	<detailed_description />
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Single [ QTc , QTcB QTcF ] le 450 msec ; QTc le 480 msec subject Bundle Branch Block . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Female subject 18 45 year age inclusive , time signing informed consent . A female subject eligible participate : Childbearing potential abstinent agree use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 48 hour post last dose . Body weight great 50 kg BMI within range 1929.9 kg/m2 ( inclusive ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol/urine cotinine screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummels , exotic citrus fruit , grapefruit hybrid 7 day prior first dose study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>preterm labor</keyword>
</DOC>